Polyurethane having an antithrombogenic coating
The invention concerns polyurethane (PUR) having an antithrombogenic coating, wherein the antithrombogenic coating comprises at least one antithrombogenic substance covalently bound to a surface of the PUR via at least two bonds, wherein a first of said bonds is an amide bond between the surface of the PUR and a polyethyleneimine (PEI) and a second of said bonds is between the PEI and the antithrombogenic substance, wherein the surface of the PUR had been activated by use of a carbon dioxide plasma or a plasma modified by addition of carbon dioxide before the first of said bonds was formed.
1. An antithrombogenic polyurethane (PUR) having an antithrombogenic coating, wherein the antithrombogenic coating comprises at least one antithrombogenic substance covalently bound to a surface of the PUR via at least two bonds, wherein a first of said bonds is an amide bond between the surface of the PUR and a polyethyleneimine (PEI) and a second of said bonds is between the PEI and the antithrombogenic substance, wherein the surface of the PUR had been activated by use of a carbon dioxide plasma or a plasma modified by addition of carbon dioxide before the first of said bonds was formed.
2. PUR according to claim 1 , wherein the PUR is an elastomeric PUR or an elastomeric polycarbonate based PUR.
3. PUR according to claim 2 , wherein the PUR is synthesized from polycarbonate glycol, methylene diisocyanate, ethylene diamine, and diaminocyclohexane.
4. PUR according to claim 1 , wherein the PEI is branched or a dendrimer.
5. PUR according to claim 1 , wherein the second bond is an amide bond.
6. PUR according to claim 1 , wherein the antithrombogenic substance is heparin modified to comprise a reactive group in unbound condition or antithrombin III (AT III) or any other antithrombogenic substance having at least one carboxy group, ketone group, aldehyde group or amino group in unbound condition.
7. PUR according to claim 1 , wherein the modified plasma is a nitrogen plasma or an argon plasma.
8. PUR according to claim 1 , comprising a medicament comprised of the PUR.
9. PUR according to claim 1 , comprising a medicament or medical device comprised of the PUR adapted for use in the treatment of thrombosis or a risk of getting thrombosis.
10. A medical device adapted to be inserted or contacted temporarily or permanently into or with a bloodstream or adapted to be inserted temporarily or permanently into a body of a mammal or a human being, wherein a surface of said medical device comprises the PUR according to claim 1 .
11. A method of producing an antithrombogenic polyurethane (PUR) comprising the following steps:
a) activation of an antithrombogenic coating on a surface comprised of polyurethane PUR, wherein activation is performed by use of a plasma, and wherein i) the plasma is a carbon dioxide plasma, or ii) the plasma is modified by addition of carbon dioxide,
b) a first coupling, wherein a polyethyleneimine (PEI) is coupled to the PUR surface, and
c) a second coupling, wherein at least one antithrombogenic substance is coupled to the PEI,
to produce an antithrombogenic PUR surface, the antithrombogenic surface comprised of at least one antithrombogenic substance covalently bound to a surface of the PUR via at least two bonds, wherein a first of said bonds is an amide bond between the surface of the PUR and a PEI and a second of said bonds is between the PEI and the antithrombogenic substance.
12. Method according to claim 11 , wherein the PUR surface is exposed to air or oxygen between steps a) and b).
13. Method according to claim 12 , wherein the PUR surface is incubated in water, a buffer, a saline solution, or an isotonic saline solution between steps a) and b).
14. Method according to claim 11 , wherein the first coupling or the second coupling is performed by use of N-Hydroxysuccinimide (NHS) and N,N′-Dicyclohexylcarbodiimide (DCC) or 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC).
15. Method according to claim 14 , wherein the modified plasma is a nitrogen plasma or an argon plasma.
16. Method according to claim 11 , wherein the first and the second coupling is performed by use of N-Hydroxysuccinimide (NHS) and N,N′-Dicyclohexylcarbodiimide (DCC) or 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC).
17. Method according to claim 13 , wherein the PUR surface is exposed to air or oxygen between steps a) and b) after the exposure to air or oxygen.
18. Method according to claim 11 , wherein the PUR surface is incubated in water, a buffer, a saline solution, or an isotonic saline solution between steps a) and b).
19. Method according to claim 11 , wherein the modified plasma comprises a nitrogen plasma or an argon plasma.
20. Method according to claim 11 , wherein the PUR is formed into a medicament or a medical device adapted for use in a bloodstream.